Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects

被引:12
作者
Toublanc, Nathalie [1 ]
Du, Xinlu [2 ]
Liu, Yun [3 ]
Chen, Qian [3 ]
Singh, Pritibha [4 ]
Chan, Robert [5 ]
Stockis, Armel [1 ]
机构
[1] UCB Pharma, B-1420 Braine Lalleud, Belgium
[2] UCB Pharma, Shanghai, Peoples R China
[3] Shanghai Xuhui Cent Hosp, Shanghai, Peoples R China
[4] UCB Pharma, Monheim, Germany
[5] UCB Pharma, Tokyo, Japan
关键词
DOSE PHARMACOKINETICS; PLACEBO;
D O I
10.1007/s40261-015-0303-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objective Levetiracetam is available in China as adjunctive oral therapy for partial-onset seizures. This study was conducted to evaluate the bioequivalence between single-dose intravenous infusion and oral levetiracetam 1500 mg (Part A), and to assess the pharmacokinetics of multiple-dose intravenous infusion at the same dose (Part B) in healthy Chinese subjects. Methods Part A was an open-label, crossover comparison (intravenous vs. oral), while Part B was a double-blind, parallel-group study of intravenous levetiracetam versus intravenous placebo administered for 5 days. Results Bioequivalence was demonstrated between the 45-min intravenous infusion and oral tablets, with geometric mean area under the plasma concentration-time curve (AUC) from time 0 to infinity (AUC(infinity)) 492.3 and 506.8 mu g.h/mL, and geometric mean maximum concentration (C-max) 65.12 and 55.93 mu g/mL for intravenous infusion and oral dosing, respectively. Linear pharmacokinetics were demonstrated (geometric least-squares mean AUC during the dosing interval tau at steady state (AUC(tau,ss)) 475.6 mu g.h/mL; geometric least-squares mean AUC(infinity) after single dose 501.7 mu ga.h/mL; linearity factor = 0.948). Geometric mean C-max (77.44 mu g/mL) and AUC (tau,ss) (475.6 mu g.h/mL) of intravenous infusion levetiracetam 1500 mg after multiple doses were within the expected range, based on their respective single-dose values and the terminal half-life of levetiracetam after a single dose (7.13 h). A theoretical accumulation of approximately 40 % would be expected after multiple doses, which is consistent with the calculated accumulation of 18.0 and 43.5 % (R-max and R-AUC, respectively). Conclusions Intravenous infusion of levetiracetam is bioequivalent to oral levetiracetam in healthy Chinese subjects and is a suitable alternative for levetiracetam administration in patients who are temporarily unable to take their medication orally.
引用
收藏
页码:495 / 503
页数:9
相关论文
共 8 条
  • [1] Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures
    Baulac, Michel
    Brodie, Martin J.
    Elger, Christian E.
    Krakow, Karsten
    Stockis, Armel
    Meyvisch, Paul
    Falter, Ursula
    [J]. EPILEPSIA, 2007, 48 (03) : 589 - 592
  • [2] Pharmacokinetic profile of levetiracetam: toward ideal characteristics
    Patsalos, PN
    [J]. PHARMACOLOGY & THERAPEUTICS, 2000, 85 (02) : 77 - 85
  • [3] Effects of antiepileptic comedication on levetiracetam pharmacokinetics:: a pooled analysis of data from randomized adjunctive therapy trials
    Perucca, E
    Gidal, BE
    Baltès, E
    [J]. EPILEPSY RESEARCH, 2003, 53 (1-2) : 47 - 56
  • [4] Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects
    Ramael, S
    De Smedt, F
    Toublanc, N
    Otoul, C
    Boulanger, P
    Riethuisen, JM
    Stockis, A
    [J]. CLINICAL THERAPEUTICS, 2006, 28 (05) : 734 - 744
  • [5] Levetiracetam intravenous infusion: A randomized, placebo-controlled safety and pharmacokinetic study
    Ramael, Steven
    Daoust, Agnes
    Otoul, Christian
    Toublanc, Nathalie
    Troenaru, Mona
    Lu, Zhihong
    Stockis, Armel
    [J]. EPILEPSIA, 2006, 47 (07) : 1128 - 1135
  • [6] Stockis Armel, 2009, Expert Rev Clin Pharmacol, V2, P339, DOI 10.1586/ecp.09.16
  • [7] Levetiracetam Pharmacokinetics in Japanese Subjects with Renal Impairment
    Yamamoto, Junichi
    Toublanc, Nathalie
    Kumagai, Yuji
    Stockis, Armel
    [J]. CLINICAL DRUG INVESTIGATION, 2014, 34 (11) : 819 - 828
  • [8] Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects
    Zhao, Qian
    Jiang, Ji
    Li, XiaoMing
    Lu, Zhihong
    Hu, Pei
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (05) : 614 - 617